Alice Blue Home
URL copied to clipboard

Trending News

Wanbury ramps up Tanuku facility, targets ₹100 Cr revenue in FY 2026-27; Stock rallies 12%

Wanbury Limited started commercial production of a high-potent anaesthetic API at its Tanuku facility, with expected Rs 18 crore revenue in Q4 FY26 and further growth in FY27.
Wanbury logo displayed over pharmaceutical production line

Introduction

Leading pharmaceutical manufacturer commenced commercial production of a high-potent anaesthetic API at its Tanuku facility, with additional high-value APIs planned for FY27 revenue growth.

Alice Blue Image

Also Read: Coforge gains 3% after partnering with Innovaccer to accelerate AI adoption in healthcare

Share price movement of Wanbury

On January 28, 2026, Wanbury Ltd opened at ₹166.15, up 1.88% from its previous close of ₹163.10. The stock reached a high of ₹182.80 (12.05%) and a low of ₹162.75. By 2:29 PM, it traded at ₹174.00, a 6.68% increase, with a market cap of ₹607.12 crore.

Wanbury Starts API Production

Wanbury Limited announced commercial production of a high-potent anaesthetic API at its Tanuku, Andhra Pradesh facility, targeting revenue contribution beginning Q4 FY26 and expansion in FY27 for domestic global markets.

The new API is expected to generate about Rs 18 crore revenue in Q4 FY26, strengthening Wanbury’s API portfolio and near-term earnings outlook from commercial production at Tanuku facility site.

Wanbury said a multipurpose intermediate block at Tanuku will be ready by March 2026, enabling four additional APIs and projected over Rs 100 crore revenue in FY27 from global demand.

Stock performance of Wanbury for Period of 1 week, 6 months, and 1 year

Wanbury Ltd delivered a -9.38% return over the past week, declined 39.2% in the past 6 months, and fell 25.6% over the past 1 year.

Alice Blue Image

Also Read: Airfloa Rail zooms 4% after signing MoU with Janatics for automatic train doors

Shareholding pattern of Wanbury

ParticularsDec 2025Sep 2025Jun 2025
Promoter43%39.60%39.60%
FII0.70%0.80%1.60%
DII0.00%0.00%0.00%
Public56.20%59.60%58.80%

About Wanbury

Wanbury Ltd (NSE: WANBURY), founded in 1988, is a pharmaceutical company specializing in global API sales, domestic branded formulations, and research, with presence in over 50 countries.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Why is Wanbury Ltd share price rising today?

A: Wanbury Limited starts commercial production of anaesthetic API at Tanuku facility, expects Rs 18 crore revenue in Q4 FY26 and additional APIs by March 2026.

Q: What is Wanbury Ltd’s main business focus?

A: Wanbury Ltd focuses on pharmaceutical products, including global API sales, domestic branded formulations, and research with presence in over 50 countries.

Q: What is the 52-week high and low of Wanbury Ltd stock?

A: Wanbury Ltd stock has a 52-week high of Rs 330.00 and a 52-week low of Rs 155.00.

Submit the form, and get to know how you scored!!!

Gainers & Losers

Read More News
गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत
Global Market

गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत

मेटा डिस्क्रिप्शन: गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12 के संकेतों से भारतीय बाजारों में सकारात्मक शुरुआत की उम्मीद है। कच्चे

*T&C apply